References
- RollisonDEHowladerNSmithMTEpidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States 2001–2004, using data from the NAACCR and SEER programsBlood2008112455218443215
- GuralnikJMEisenstaedtRSFerrucciLPrevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemiaBlood20041042263226815238427
- HoweRBPorwit-MacDonaldAWanatRThe WHO classification of MDS does make a differenceBlood20041033265327014684416
- AlessandrinoEPAmadoriSCazzolaMMyelodysplastic syndromes: recent advancesHaematologica2001861124115711694400
- Hellström-LindbergEWillmanCBarrettJSaunthararajahYAchievements in understanding and treatment of myelodysplastic syndromesAmerican Society of Hematology Education Program Book200011013211701538
- De WitteTSuciuSVerhoefGIntensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDSBlood2001982326233111588026
- GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood199789207920889058730
- ChesonBDBennettJMKantarjianHReport of an international working group to standardize response criteria for myelodysplastic syndromesBlood2000963671367411090046
- AdèsLBoehrerSPrebetTEfficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyBlood20091133947395218987358
- MalcovatiLGermingUKuendgenATime-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesJ Clin Oncol2007253503351017687155
- GermingUHildebrandtBPfeilstöckerMRefinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)Leukemia2005192223223116193087
- Garcia-ManeroGShanJFaderlSA prognostic score for patients with lower risk myelodysplastic syndromeLeukemia20082253854318079733
- KantarjianHO’BrienSRavandiFProposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer20081131351136118618511
- BullingerMHasfordJEvaluating quality-of-life measures for clinical trials in GermanyControl Clin Trials19911291S105S1663863
- RichTInnominatoPFBoernerJElevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancerClin Cancer Res2005111757176415755997
- MeyersCAAlbitarMEsteyECognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndromeCancer200510478879315973668
- HsuHCLeeYMTsaiWHCirculating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndromeOncology200263646912187073
- TefferiAIron chelation therapy for myelodysplastic syndrome: If and whenMayo Clin Proc20068119719816471074
- ChavesPHFunctional outcomes of anemia in older adultsSemin Hematol20084525526018809096
- FriedLPTangenCMWalstonJFrailty in older adults: evidence for a phenotypeJ Gerontol A Biol Sci Med Sci200156M146M15611253156
- ZakaiNAKatzRHirschCA prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health StudyArch Intern Med20051652214222016246985
- ChavesPHXueQLGuralnikJMWhat constitutes normal hemoglobin concentration in community-dwelling disabled older women?J Am Geriatr Soc2004521811181615507056
- BowenDCulliganDJowittSGuidelines for the diagnosis and therapy of adult myelodysplastic syndromesBr J Haematol200312018720012542475
- JansenAJEssink-BotMLBeckersEAQuality of life measurement in patients with transfusion-dependent myelodysplastic syndromesBr J Haematol200312127027412694248
- ListAFBaerMRSteensmaDDeferasirox (ICL670; Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndrome [abstract 1470]Blood (ASH Annual Meeting Abstracts)2007110440a
- RoseCBrechignacSVassiliefDPositive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients; a prospective analysis by the GFM [abstract 249]Blood (ASH Annual Meeting Abstracts)200711080a
- Hellström-LindbergEEfficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studiesBr J Haematol19958967717833279
- A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic SyndromesBr J Haematol1998103107010749886322
- Hellström-LindbergENegrinRSteinRErythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive modelBr J Haematol1997993443519375752
- TerposEMougiouAKouraklisAProlonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patientsBr J Haematol200211817418012100145
- GiraldoPNomdedeuBLoscertalesJDarbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromesCancer20061072807281617115424
- GolshayanARJinTMaciejewskiJEfficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromesBr J Haematol200713712513217391492
- NCCN practice guidelines for the myelodysplastic syndromesNational Comprehensive Cancer NetworkOncology199812538010028503
- TiuRVSekeresMAThe role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromesExpert Opin Biol Ther200881021103018549331
- GaliliNCernyJRazaACurrent treatment options: impact of cytogenetics on the course of myelodysplasiaCurr Treat Options Oncol2007811712817634837
- De WitteTZwaanFHermansJAllogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)Br J Haematol1990741511552180469
- KuendgenAStruppCAivadoMMyelodysplastic syndromes in patients younger than age 50J Clin Oncol2006245358536517088566
- SierraJPérezWSRozmanCBone marrow transplantation from HLA-identical sibvling as treatment for myelodysplasiaBlood20021001997200412200358
- WarlickEDCiocADeforTAllogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burdenBiol Blood Marrow Transplant200915303819135940
- AppelbaumFRAndersonJAllogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS scoreLeukemia199812Suppl 1S25S299777891
- CutlerCSLeeSJGreenbergPA decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeBlood200410457958515039286
- BaccaraniMTuraSDifferentiation of myeloid leukaemic cells: new possibilities for therapyBr J Haematol197942485487289407
- WischJSGriffinJDKufeDWResponse of preleukemic syndromes to continuous infusion of low-dose cytarabineN Engl J Med1983309159916026646185
- MillerKBKimKMorrisonFSThe evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup studyAnn Hematol1992651621681420504
- ClarkREIsmailSAJacobsAA randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndromeBr J Haematol19876677833297129
- GarewalHGreenbergPListAN-(4-hydroxyphenyl) retinamide [4-HPR] therapy in myelodysplastic syndromes (MDS): possible disease acceleration by retinoidsBlood (ASH Annual Meeting Abstracts)198770228a
- ChesonBDThe myelodysplastic syndromes: current approaches to therapyAnn Intern Med19901129329412187393
- SabaHIShamimFIsmailRAcute leukemic transformation in myelodysplastic syndrome. [abstract]Blood (ASH Annual Meeting Abstracts)199280459a
- Gafter-GviliAFraserAPaulMLeiboviciLMeta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patientsAnn Intern Med200514297999515968013
- ListADewaldGBennettJLenalidomide in the myelodysplastic syndrome with chromosome 5q deletionN Engl J Med20063551456146517021321
- RazaAReevesJAFeldmanEJPhase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qBlood2008111869317893227
- SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol2002202429244012011120
- FenauxPSantiniVHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol20091022323219230772
- KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer20061061794180316532500
- MolldremJJCaplesMMavroudisDAntithymocyte globulin for patients with myelodysplastic syndromeBr J Haematol1997996997059401087
- SorrorMLSandmaierBMStorerBEComorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantationJ Clin Oncol2007254246425417724349
- SloandEMWuCOGreenbergPFactors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapyJ Clin Oncol2008262505251118413642
- SaunthararajahYNakamuraRNamJMHLA-DR15 (DR2) is ovvererepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeBlood20021001570157412176872